摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Nonatriaconta-9,30-diene-18,20,22-trione

中文名称
——
中文别名
——
英文名称
Nonatriaconta-9,30-diene-18,20,22-trione
英文别名
nonatriaconta-9,30-diene-18,20,22-trione
Nonatriaconta-9,30-diene-18,20,22-trione化学式
CAS
——
化学式
C39H70O3
mdl
——
分子量
587.0
InChiKey
RZUYRSAKBYELDE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    14.6
  • 重原子数:
    42
  • 可旋转键数:
    34
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.82
  • 拓扑面积:
    51.2
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • [EN] TREATMENT OF NEURODEGENERATIVE CONDITIONS<br/>[FR] TRAITEMENT D'ETATS NEURODEGENERATIFS
    申请人:BTG INT LTD
    公开号:WO2005018632A1
    公开(公告)日:2005-03-03
    A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of Ϝ-linolenic acid, dihomo-Ϝ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels.
    提供了一种治疗神经退行性疾病患者的方法,包括向该患者施用含有甘油基团和脂肪酸基团的治疗有效剂量的脂质甘油酯,所述脂肪酸基团选自Ϝ-亚麻酸、二油酸花生四烯酸组成的群体,其特点在于所选的脂肪酸基团附着在甘油基团的sn-2位置。最好的方法是,脂质被施用的持续时间和剂量足以维持或提高患者体内TGF-β1平至治疗平。
  • Treatment for neurodegenerative conditions
    申请人:BTG International Limited
    公开号:EP2324828A1
    公开(公告)日:2011-05-25
    A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo- γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels.
    提供了一种治疗需要治疗的神经退行性疾病患者的方法,该方法包括向该患者施用治疗有效剂量的脂质甘油酯,该脂质甘油酯包括甘油分子和脂肪酸分子,脂肪酸分子选自γ-亚麻酸、二氢-γ-亚麻酸花生四烯酸组成的组,其特征在于所选脂肪酸分子在其sn-2位连接到甘油分子上。优选的方法是,脂质的给药时间和剂量足以使患者体内的 TGF-β1 平维持或升高到治疗平。
  • TREATMENT OF NEURODEGENERATIVE CONDITIONS
    申请人:BTG INTERNATIONAL LIMITED
    公开号:EP1660071A1
    公开(公告)日:2006-05-31
  • Treatment of Neurodegenerative Conditions
    申请人:Harbige Laurence S.
    公开号:US20080194684A1
    公开(公告)日:2008-08-14
    A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β levels in the patient to therapeutic levels.
  • Treatment of neurodegenerative conditions
    申请人:Harbige Lawrence S.
    公开号:US20100113595A1
    公开(公告)日:2010-05-06
    A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels.
查看更多